NASDAQ$PBYI
Puma Biotechnology Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Puma Biotechnology Inc Q1 fiscal 2026: $44.8M revenue, $3.8M net loss
reported net income, the Company cannot ensure that it will continue to do so and will need to continue to generate significant revenue to sustain operations and successfully commercialize neratinib. (SEC accession 0001437749-26-015633)
- Revenue: $44.8M
- Net loss: $3.8M
- Diluted EPS: $-0.07
- Operating income: $-3.8M
Headline financials
Revenue & EPS history
Puma Biotechnology · Revenue · Quarterly
$44.8M
Revenue by segment
Puma Biotechnology · $56.1M total across 2 segments · Q3 2023
- Product Revenue, Net$51.6M—92.0%
- Royalty Revenue$4.5M+60.7%8.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-1.6%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+4.7%
Avg return
30 days after
47%
21 / 45 earnings
Positive
+36.4%
Q4 2018
Best reaction
-45.8%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.6% | -6.0% | — | |
| Q4 2025 | -25.1% | -15.8% | -20.0% | |
| Q3 2025 | +21.8% | +1.8% | +8.2% | |
| Q1 2025 | -4.6% | -5.5% | +21.2% | |
| Q4 2024 | +19.7% | +18.4% | +5.0% | |
| Q3 2024 | -5.9% | +4.9% | +2.0% | |
| Q2 2024 | +6.7% | +12.3% | -30.4% | |
| Q1 2024 | -1.8% | -4.0% | -22.2% | |
| Q4 2023 | -10.8% | -21.5% | -19.7% | |
| Q3 2023 | +4.9% | +9.4% | +41.5% | |
| Q2 2023 | +5.8% | +13.3% | +2.5% | |
| Q1 2023 | +19.8% | +19.4% | +35.0% | |
| Q4 2022 | -20.1% | -26.6% | -23.1% | |
| Q3 2022 | +25.5% | +50.9% | +106.0% | |
| Q2 2022 | +23.5% | +17.4% | -17.0% | |
| Q1 2022 | -19.1% | -26.0% | -4.9% | |
| Q4 2021 | +13.5% | +25.7% | +34.2% | |
| Q3 2021 | -39.1% | -42.2% | -54.6% | |
| Q2 2021 | +3.6% | +3.6% | +7.9% | |
| Q1 2021 | +1.6% | -0.8% | +17.0% | |
| Q4 2020 | -11.9% | -11.9% | -12.6% | |
| Q3 2020 | -11.0% | +1.3% | +31.8% | |
| Q2 2020 | -5.7% | -7.9% | -11.6% | |
| Q1 2020 | +11.2% | +23.1% | +6.4% | |
| Q4 2019 | -2.4% | -18.8% | -43.9% | |
| Q3 2019 | +4.2% | +18.0% | +9.1% | |
| Q2 2019 | +26.7% | +25.8% | +22.1% | |
| Q1 2019 | -38.6% | -41.5% | -53.9% | |
| Q4 2018 | +36.4% | +35.3% | +35.9% | |
| Q3 2018 | -45.8% | -39.5% | -37.3% | |
| Q2 2018 | -7.5% | -7.1% | -2.1% | |
| Q1 2018 | -19.0% | -18.9% | -24.3% | |
| Q4 2017 | +8.7% | +16.7% | +4.1% | |
| Q3 2017 | -22.2% | -24.3% | -23.9% | |
| Q2 2017 | -11.6% | -1.7% | +28.0% | |
| Q1 2017 | +1.5% | +4.3% | +163.9% | |
| Q4 2016 | -10.6% | -8.3% | +1.4% | |
| Q3 2016 | +21.3% | -0.5% | -9.4% | |
| Q3 2015 | -9.6% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q1 2013 | +3.7% | — | — | |
| Q3 2012 | -6.4% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +1.9% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro